Unusual Machines (NYSEMKT: UMAC) stock had a five-day trading stretch that was unusual in a good way. Encouraged by very bullish comments from the drone component maker's leader, investors piled into the stock, sending it up by double digits. Over the course of the week, according to data compiled by S&P Global Market Intelligence , Unusual Machines' stock ballooned more than 15% higher in price. ...
Unusual Machines (NYSEMKT: UMAC) stock had a five-day trading stretch that was unusual in a good way. Encouraged by very bullish comments from the drone component maker's leader, investors piled into the stock, sending it up by double digits. Over the course of the week, according to data compiled by S&P Global Market Intelligence , Unusual Machines' stock ballooned more than 15% higher in price. On Tuesday, White Diamond Research conducted an interview with Unusual Machines CEO Allan Evans. In the conversation, Evans repeatedly emphasized that the company's wares are in extremely high demand, not least because of the two leading wars in the world. But even if those were to end, the company would still be operating at a high pitch. Image source: Getty Images. Continue reading
Matinas BioPharma ( NYSE: MTNB ) said on Friday it received a notice from NYSE American on April 2, 2026, for non-compliance with Section 1003(a)(i) listing standard. NYSE American said the company failed to meet stockholders’ equity requirements under Sections 1003(a)(i)-(iii), which mandate minimum equity of $2M, $4M, or $6M depending on recent loss history. The notice said the company had stock...
Matinas BioPharma ( NYSE: MTNB ) said on Friday it received a notice from NYSE American on April 2, 2026, for non-compliance with Section 1003(a)(i) listing standard. NYSE American said the company failed to meet stockholders’ equity requirements under Sections 1003(a)(i)-(iii), which mandate minimum equity of $2M, $4M, or $6M depending on recent loss history. The notice said the company had stockholders’ equity of $4.83M as of Dec. 31, 2025, with losses over the past five fiscal years, making it ineligible for any exemption under Section 1003(a). The company is now subject to Section 1009 procedures and has until May 2, 2026, to submit a compliance plan, with up to 18 months from the notice date to regain compliance. More on Matinas Biopharma Financial information for Matinas Biopharma